{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Lung+Cancer+With+FGFR1+Amplification",
    "query": {
      "condition": "Squamous Lung Cancer With FGFR1 Amplification"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T02:12:19.706Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02109016",
      "title": "A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Squamous Non-Small Cell Lung Cancer",
        "NSCLC",
        "Small Cell Lung Cancer",
        "SCLC",
        "Lung Cancer",
        "Advanced Lung Cancer",
        "Metastatic Lung Cancer",
        "Stage IV Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Lucitanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clovis Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2014-04",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2019-07-29",
      "last_synced_at": "2026-05-22T02:12:19.706Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02109016"
    },
    {
      "nct_id": "NCT02965378",
      "title": "Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "FGFR1 Gene Amplification",
        "FGFR1 Gene Mutation",
        "FGFR2 Gene Amplification",
        "FGFR2 Gene Mutation",
        "FGFR3 Gene Amplification",
        "FGFR3 Gene Mutation",
        "Recurrent Squamous Cell Lung Carcinoma",
        "Stage IV Squamous Cell Lung Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "FGFR Inhibitor AZD4547",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2014-10",
      "completion_date": "2019-10",
      "has_results": true,
      "last_update_posted_date": "2021-05-27",
      "last_synced_at": "2026-05-22T02:12:19.706Z",
      "location_count": 1083,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 672 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02965378"
    },
    {
      "nct_id": "NCT01948141",
      "title": "Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Non-small Cell Lung Cancer",
        "Squamous Cell Lung Cancer",
        "Stage III Non-small Cell Lung Cancer",
        "Stage IV Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "nintedanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2014-01-30",
      "completion_date": "2016-08-16",
      "has_results": true,
      "last_update_posted_date": "2017-06-08",
      "last_synced_at": "2026-05-22T02:12:19.706Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • Cleveland, Ohio",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01948141"
    },
    {
      "nct_id": "NCT01004224",
      "title": "A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3",
        "Squamous Lung Cancer With FGFR1 Amplification",
        "Bladder Cancer With FGFR3 Mutation or Fusion",
        "Advanced Solid Tumors With FGFR1 Amplication",
        "Advanced Solid Tumors With FGFR2 Amplication",
        "Advanced Solid Tumors With FGFR3 Mutation"
      ],
      "interventions": [
        {
          "name": "BGJ398",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2009-12-11",
      "completion_date": "2018-10-08",
      "has_results": false,
      "last_update_posted_date": "2019-10-04",
      "last_synced_at": "2026-05-22T02:12:19.706Z",
      "location_count": 16,
      "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01004224"
    }
  ]
}